Join us for this re-broadcast of the Live Event at WCLC 2023 as we discuss incorporating MET inhibitors into critical treatment decisions. It will cover evidence-based and consensus-guided recommendations and the latest data from completed and ongoing clinical trials demonstrating the application of MET inhibitors in the treatment of NSCLC. Our goals for this symposium are to further the adoption of best practices for patient selection and molecular profiling and explore global regulatory approvals and data that indicate how MET inhibitors could overcome aberrant EGFR TKI treatment resistance.
Please see below for when the Live Broadcast will begin in your time zone:
- 6 PM CEST
- 12 PM ET
- 9 AM PT